Arena Pharmaceuticals Inc

Arena Pharmaceuticals — Shareholder Meeting (June 2016)

7 slides from Arena Pharmaceuticals's shareholder meeting presentation, Jun 10, 2016

  1. Slide 1: June 2016 Annual Meeting

    J u n e 2 0 1 6 Annual Meeting

  2. Slide 2: Forward Looking Statement

    Forward Looking Statement 2 This presentation includes forward-looking statements that involve a number of risks and uncertainties, including statements about our and others’ focus, mission, goals, strategy, approach, plans, timelines, milestones and expectations; R&D programs and BELVIQ, including

  3. Slide 3: Corporate Priorities: Advance Novel Clinical Programs

    Corporate Priorities 3  Etrasimod (APD334) in ulcerative colitis (P2 ongoing)  Ralinepag (APD811) in pulmonary arterial hypertension (P2 ongoing)  APD371 in pain indications (P2 ready)  Evaluate expansion into other indications Advance Novel Clinical Programs 1

  4. Slide 4: Corporate Priorities: Streamline Operations

    Corporate Priorities (continued)  Etrasimod (APD334) in ulcerative colitis (P2 ongoing)  Ralinepag (APD811) in pulmonary arterial hypertension (P2 ongoing)  APD371 in pain indications (P2 ready)  Evaluate expansion into other indications Advance the Novel Clinical Programs 1  Define and focus o

  5. Slide 5: Corporate Priorities: Support Collaborations

    Corporate Priorities (continued) 5  Etrasimod (APD334) in ulcerative colitis (P2 ongoing)  Ralinepag (APD811) in pulmonary arterial hypertension (P2 ongoing)  APD371 in pain indications (P2 ready)  Evaluate expansion into other indications Advance the Novel Clinical Programs 1  Define and focus

  6. Slide 6: Pipeline

    6 Program Indication Pre- Clinical Phase 1 Phase 2 Phase 3 Post Market Commercial Rights Internal Programs Etrasimod (APD334) S1P1 Modulator Ulcerative Colitis Arena: Worldwide Ralinepag (APD811) PGI2 Agonist PAH APD371 CB2 Agonist Pain Partnered Programs BELVIQ (CVOT Study) CV Outcomes, T2D Convers

  7. Slide 7: Thank You

    Thank You 7

Arena Pharmaceuticals — Shareholder Meeting (June 2016) on 6ix